Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents
References (22)
- et al.
Plasma timolol in glaucoma patients
Ophthalmology
(1984) - et al.
Underdiagnosis of asthma in the elderly
Br J Dis Chest
(1987) - et al.
Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma
Ophthalmology
(1994) - et al.
A study of the prevalence of eye disease in the elderly in an English community
Trans Ophthalmol Soc UK
(1985) - et al.
Double-masked three-period crossover investigation of timolol in control of raised intraocular pressure
Eye
(1993) - et al.
Timolol induced bronchospasm in asthmatic bronchitis
JAMA
(1981) - et al.
Improved lung function tests on changing from topical timolol. Non-selective beta-blockade impairs the lung function tests of elderly people
Eye
(1993) - et al.
Betaxolol. A new beta-adrinergic blocking agent for treatment of glaucoma
Arch Ophthalmol
(1982) - et al.
Dipivefrin and epinephrine treatment of elevated intraocular pressure
Arch Ophthalmol
(1979) Mental impairment in the elderly
J R Col Physicians Lond
(1973)
There are more references available in the full text version of this article.
Cited by (92)
Ophthalmic administration of a 10-fold-lower dose of conventional nanoliposome formulations caused levels of intraocular pressure similar to those induced by marketed eye drops
2018, European Journal of Pharmaceutical SciencesCitation Excerpt :The effectiveness of the marketed ocular TM products is restricted by extremely low bioavailability of the drug. Ophthalmic TM delivery has certain restrictions due to the structure of the eyeball: some instilled amount is absorbed by the conjunctiva, passing into the systemic circulation, without exerting its therapeutic effect; also, the frequent instillation can generate an excessive loss of drug through nasolacrimal drainage causing respiratory and cardiovascular side effects (Diggory et al., 1995). In addition, the mucin present in the tear film has a protective effect preventing tear evaporation due to the formation of a hydrophilic gel layer, but also this glycoprotein limits the penetration of the drug.
Dipivefrine
2007, xPharm: The Comprehensive Pharmacology ReferenceManagement of open‐angle glaucoma by primary eye‐care practitioners: toward a personalised medicine approach
2021, Clinical and Experimental OptometrySelective laser trabeculoplasty versus topical medication as initial glaucoma treatment: The glaucoma initial treatment study randomised clinical trial
2020, British Journal of OphthalmologyPulmonary safety of ophthalmic beta-blockers: a nationwide registry-based cohort study
2018, Acta Ophthalmologica
Copyright © 1995 Published by Elsevier Ltd.